GlassScriptPhysician profile
Nina Bhambhani
NPI 1831147545
$175,032.27
in general payments reported to CMS, 2019-2025
29 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $26K · 2021: $17K · 2022: $44K · 2023: $20K · 2024: $8,112 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $7,987 · Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,225.00 |
| Travel and Lodging | $7,987.37 |
| Food and Beverage | $2,597.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171,293.45 | 2019-2025 | Rinvoq, Skyrizi, Ubrelvy |
| Amgen INC. | $531.18 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $506.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $471.85 | 2021-2023 | Nucala, Benlysta |
| Janssen Biotech, INC. | $405.61 | 2019-2025 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $316.84 | 2019-2022 | |
| Abbott Laboratories | $161.09 | 2025 | Esprit |
| Cumberland Pharmaceuticals, INC. | $159.71 | 2021 | |
| Radius Health, INC. | $141.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $117.43 | 2019 | |
| Sobi, INC | $97.33 | 2024 | |
| Lilly USA, LLC | $96.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.28 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.96 | 2019-2020 | |
| Mylan Specialty L.P. | $67.91 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $66.80 | 2023 | Opsumit |
| Medexus Pharma, INC. | $60.44 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $59.99 | 2022 | |
| Genentech USA, INC. | $48.98 | 2019 | |
| Aurinia Pharma U.S., INC. | $37.26 | 2021-2022 | |
| Amarin Pharma, INC. | $36.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $32.98 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $29.68 | 2019 | |
| Genzyme Corporation | $26.63 | 2020 | |
| Philips North America LLC | $24.56 | 2019 | |
| Antares Pharma, INC. | $23.89 | 2020 | |
| Ironwood Pharmaceuticals, INC | $22.37 | 2021 | |
| Axogen | $21.61 | 2025 | |
| Hikma Pharmaceuticals USA | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Bhambhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.